ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug Administration (FDA).
ERYTECH Provides Regulatory Update
- Post author:Marianne Duparc
- Post published:August 24, 2022
- Post category:Newsroom